Tracking kids on growth hormone therapy for years to come
NCT ID NCT05602766
Summary
This study is monitoring the long-term safety and growth effects of Ngenla, an approved treatment for children with growth hormone deficiency. It will follow children (boys under 15, girls under 13) who are starting Ngenla treatment for the first time. Researchers will track their health, growth, and any side effects until late 2027 to better understand the medicine's long-term profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROWTH HORMONE DEFICIENCY WITHOUT EPIPHYSEAL CLOSURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.